News headlines about Pacific Biosciences of California (NASDAQ:PACB) have been trending positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.33 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.7941607057081 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of PACB stock opened at $4.11 on Tuesday. Pacific Biosciences of California has a fifty-two week low of $2.02 and a fifty-two week high of $5.70. The firm has a market capitalization of $552.84 million, a PE ratio of -4.72 and a beta of 1.57. The company has a debt-to-equity ratio of 0.17, a current ratio of 4.33 and a quick ratio of 3.28.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). Pacific Biosciences of California had a negative return on equity of 95.29% and a negative net margin of 100.09%. The business had revenue of $21.58 million during the quarter, compared to analysts’ expectations of $24.45 million. During the same quarter last year, the business posted ($0.26) earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. sell-side analysts anticipate that Pacific Biosciences of California will post -0.66 earnings per share for the current fiscal year.

PACB has been the subject of a number of research analyst reports. BidaskClub cut Pacific Biosciences of California from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 18th. ValuEngine upgraded Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Piper Jaffray Companies restated a “hold” rating and issued a $3.80 price target on shares of Pacific Biosciences of California in a research report on Friday, August 3rd. Finally, Zacks Investment Research cut Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $4.77.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

See Also: Google Finance Portfolio

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.